Dr John Fox on the Economic Value of Comprehensive Genomic Profiling

Expert Interview with John Fox, MD, MHA

Dr John Fox Emphasizes the Importance of Genetic Counseling Before, After Genetic Testing

John Fox, MD, talks about the new value tools from ASCO and NCCN

What Off-Label Communications Mean for Stakeholders

Dr John Fox Discusses Financial Toxicity Associated With Multi-Drug Regimens for Multiple Myeloma

John Fox, MD, predicts if the ASCO Value Framework or NCCN Evidence Blocks will impact drug spend

Dr John Fox Discusses Expanding Comprehensive Genomic Profiling to More Tumor Types

Internal Medicine & Pediatrics at NRMC

John Fox, MD, provides perspective on collaborating with providers on clinical pathways

John Fox, MD, talks about how Priority might use the ASCO and NCCN value tools

Standardization of Biopsy Testing and Interpreting Data

What you need to know about the COVID-19 Vaccines with Dr. John Fox, MD

Empowering Stakeholders with Innovative Trial Designs

The Balancing Act of Cost vs Access to Care

Cost-Benefit Analysis in Lung Cancer

Integrating New Lung Cancer Drugs Into a Formulary

Evidence From Drug Manufacturers and Patient Access

Assessing Options in Second-Line NSCLC

Engaging Patients in Oncology Trials is a Team Effort